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Abstract Preclinical data indicated a detrimental effect of
statins on the anti-lymphoma activity of rituximab. We
evaluated the impact of concomitant statin medication on
the response and survival of patients with diffuse large B
cell lymphoma (DLBCL) receiving rituximab–cyclophos-
phamide, doxorubicin, vincristine, prednisone (R-CHOP) as
first-line therapy. Medical histories of patients with DLBCL
who were treated with R-CHOP as first-line therapy were
assessed for concomitant statin use, response after comple-
tion of chemotherapy, event-free survival (EFS), and
overall survival (OS). Furthermore, 2-[18F]fluor-2-deoxy-
glucose (FDG)-PET/CT results after completion of first-line
therapy were compared between the groups. Overall, 145
patients with DLBCL treated with R-CHOP from January
2001 to December 2009 were analyzed. Twenty-one (15%)
patients received statins throughout therapy. Five-year EFS
was 67.3% in patients without statins compared with 79%
in patients receiving statins during R-CHOP (HR, 0.47;
95% CI, 0.15–1.54, p=0.2). Five-year OS was 81.4% for
patients without statins compared with 93.3% for patients
taking statins (HR, 0.58; 95% CI 0.07–4.55, p=0.6). There
were no statistically significant differences in the rates of
complete remissions between the two groups (75% in the
non-statin group versus 86% in the statin group, p=0.45). A
trend toward a lower rate of complete metabolic responses
in FDG-PET/CT after chemotherapy was seen in patients
without statin medication compared with the patients taking
statins (84% versus 92%, p=0.068). Concomitant statin use
had no adverse impact on response to chemotherapy, EFS,
and OS in patients treated with R-CHOP for DLBCL.
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uCR Unconfirmed complete remission
PR Partial remission
SD Stable disease
PD Progressive disease
HIV Human immunodeficiency virus
HMG-CoAR 3-Hydroxy-3-methylgutaryl
coenzyme A reductase
CDC Complement-dependent cytotoxicity
ADCC Antibody-dependent cellular
cytotoxicity
mAb Monoclonal antibody
Introduction
The prognosis of patients with aggressive non-Hodgkin’s B
cell lymphoma has been improved in the last decade by
implementation of the monoclonal antibody (mAb) ritux-
imab into standard first-line chemotherapy with cyclophos-
phamide, doxorubicin, vincristine, and prednisone (CHOP)
[1, 2]. The therapeutic efficacy of rituximab is directed
against the B cell surface phosphoprotein CD20 [3]. A
recently published study reported that 3-hydroxy-3-methyl-
gutaryl coenzyme A reductase (HMG-CoAR) inhibitors,
so-called statins, are causing conformational changes of the
CD20 epitope due to statin-induced cholesterol depletion,
resulting in impaired binding of rituximab to CD20 and
reduced complement-dependent cytotoxicity (CDC) and
antibody-dependent cellular cytotoxicity (ADCC) in vitro.
The authors concluded that intake of statins may reduce the
antitumor activity of rituximab-containing chemotherapy in
lymphoma patients [4]. This finding raised concerns on the
efficacy of lymphoma treatment with rituximab in patients
who are on concomitant statin medication for cardiovascu-
lar diseases. Some authors have even suggested that
patients should discontinue statins before the onset of
rituximab-containing chemotherapy [5, 6].
Recently, one study evaluating the impact of statins on
the clinical outcome of lymphoma patients has been
reported from a Japanese group. In this study, no adverse
impact of statins on survival after R-CHOP treatment was
seen [7]. While we were preparing the final manuscript, a
second article has been published online. No differences in
outcome regarding DLBCL were reported, but, surprisingly,
patients with follicular lymphoma under statin medication
had a better event-free survival (EFS) than patients not taking
them [8]. To address this question, also in light of these two
reports, we performed a retrospective analysis of the patient
collective with diffuse large B cell lymphoma (DLBCL)
treated with rituximab and CHOP at two institutions,
University Hospital Zürich and Triemli City Hospital Zürich,
during the last 8 years. Additionally, since the value of 2-[18F]
fluor-2-deoxyglucose–positron emissions tomography/
computed tomography (FDG-PET/CT) has been shown
for the response evaluation of DLBCL [9], we were also
interested to see if differences in the metabolic response of
the lymphoma tissue were present in patients taking statins
compared to patients not using them.
Materials and methods
Records from patients with newly diagnosed DLBCL who
received R-CHOP as first-line therapy at University
Hospital Zürich or Triemli City Hospital Zürich were
reviewed. Patients with initial low-grade lymphoma and
secondary transformation to DLBCL were allowed for the
analysis, as were patients with underlying HIV infection.
Patients with primary central nervous system lymphoma or
primary testicular lymphoma were excluded from the
analysis. Data regarding lymphoma stage, international
prognostic index (IPI), extranodal disease, response to
treatment, EFS, and OS were collected. Duration and
number of chemotherapy cycles were also documented.
Patients receiving FDG-PET/CT imaging before and after
completion of chemotherapy were analyzed for differences
in the metabolic response of the lymphoma.
EFS was defined as time from first diagnosis of DLBCL
to the time of first recurrence, as verified by histology, time
to progression, as assessed by imaging during or after
completion of first-line chemotherapy, or death. Overall
survival (OS) was defined as time from initial diagnosis to
the time of death by any cause, as documented in the
patient charts.
The study was approved by our local ethics committee.
Statistics
Descriptive statistics (median and range, or counts) were
calculated for all variables. Comparisons of group
characteristics were performed using a Mann–Whitney
U test (continuous data) or Fisher's exact test (categorical).
Event-free and overall survival were calculated from the
date of diagnosis and censored at the date of last follow-
up. Survival curves were computed using the method of
Kaplan and Meier and compared using the log-rank test
[10, 11]. Values of p<0.05 were considered statistically
significant. All analyses were performed in the R program-
ming language [12].
Results
Between January 2001 and December 2009, a total of 145
patients received R-CHOP as first-line chemotherapy for
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DLBCL. De novo DLBCL was diagnosed in 135 (93%)
patients, while transformation from indolent lymphoma
occurred in ten (7%) patients. Out of the entire patient
population, 21 (15%) patients were on statin medication at
the time of chemotherapy. The statins used were atorvas-
tatin (n=9, 43%; mean daily dose 28±24 mg), simvastatin
(n=7, 33.5%; mean daily dose 31±11 mg), pravastatin (n=
4, 19%; mean daily dose 30±12 mg), and fluvastatin (n=1,
4.5%; daily dose 80 mg). No significant differences in
terms of gender, lymphoma stage, or IPI score were seen
between the two groups, but patients taking statins were
significantly older than patients without statin intake
(median 63.2 versus 56.3 years, p=0.0033; Table 1).
The median observed follow-up time for all patients was
24.4 months (range, 2.27–98 months). The entire patient
population had an EFS of 69% (95% confidence interval
(CI), 60.7–78.5%) at 5 years and an OS of 82.6% (95% CI,
70.8–96.3%) at 5 years. The median EFS and OS were not
reached during follow-up. EFS was 67.3% at 5 years for the
patient subgroup without statins compared with 79% for
patients who had received statins during R-CHOP treatment
(hazard ratio (HR), 0.47; 95% CI, 0.15–1.54, p=0.2;
Fig. 1). In addition, there was no significant difference in
OS at 5 years, with 81.4% still alive in the patient subgroup
without statins compared with 93.3% for patients who had
received them during R-CHOP treatment (HR, 0.58; 95%
CI, 0.07–4.55, p=0.6; Fig. 2).
The rate of complete remissions or unconfirmed com-
plete remissions after treatment with R-CHOP was 75% for
the patient subgroup without statins compared with 86% for
patients receiving statins (p=0.45). A subset of 69 (48%)
patients had been analyzed by FDG-PET/CT before and
after completion of chemotherapy for response assessment,
57 (83%) patients in the non-statin group, and 12 (17%)
patients in the statin group. In the non-statin group, 84% of
patients had a documented complete metabolic response
after R-CHOP compared with 92% in the statin group
(p=0.068; Table 2).
Discussion
In the present study, we did not find any statistically
significant adverse impact of statin medication on the
Table 1 Patient characteristics
Parameter Statin use
(n=21)
No statin use
(n=124)
p value
Age
≤60 years—no. (%) 8 (38) 78 (63)
>60 years—no. (%) 13 (62) 46 (37) 0.053
Median (years) 63.2 56.3
Range (years) 45.3–87.5 15.5–85.5 0.0033
Gender
Male—no. (%) 16 (76) 66 (53)
Female—no. (%) 5 (24) 58 (47) 0.059
Lymphoma stage
Early (1/2)—no. (%) 16 (76) 65 (52)
Advanced (3/4)—no. (%) 5 (24) 59 (48) 0.057
IPI score
0–1—no. (%) 11 (53) 64 (53)
2–3—no. (%) 7 (33) 48 (40)
≥4—no. (%) 3 (14) 9 (7) 0.52
Extranodal disease
Yes—no. (%) 15 (71) 81 (66)
No—no. (%) 6 (29) 42 (34) 0.8
DLBCL
De novo 19 (91) 116 (94)
Secondary transformation 2 (9) 8 (6) 0.64
HIV-associated lymphoma
Yes—no. (%) 1 (5) 10 (8)
No—no. (%) 20 (95) 114 (92) 1.0
CHOP—number of cycles
Median 6 6
Range 3–6 2–8 0.12
Rituximab—number of cycles
Median 6 6
Range 3–8 2–8 0.71
Fig. 1 Kaplan–Meier analysis of the event-free survival (EFS) of
patients without statin use compared with patients receiving statin
medication during R-CHOP treatment. EFS at 5 years was 67.3% in
patients without statins compared with 79% in patients who had
received them during treatment (HR, 0.47; 95% CI, 0.15–1.54, p=
0.2). Median EFS was not reached in both groups. Dashed line
patients with statins; solid line patients without statins
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response and the survival of patients with DLBCL treated
with R-CHOP first-line chemotherapy. On the contrary, we
observed a trend toward an improved outcome in the
subgroup of patients taking concomitant statins during
chemotherapy. Patients taking statins showed a trend
toward more complete metabolic responses in FDG-PET/
CT after completion of chemotherapy than patients without
statins (p=0.068). This result is even more remarkable
when we take into account that our patients using statins
were significantly older than the patients not taking them,
as age is known to be a negative prognostic marker for
lymphoma patients [13-16]. Our findings are in accordance
with a recently published clinical trial evaluating the same
question in a Japanese cohort. This study also showed a
trend toward improved EFS and OS in patients being on
statin medication during R-CHOP treatment without reach-
ing statistical significance [7]. Finally, a second study
reported recently also found no differences in outcome of
DLBCL patients, but, interestingly, statin use was a positive
prognostic factor in patients with follicular lymphoma
irrespective of treatment [8].
How can the discrepancy between the in vitro observed
changes of CD20 conformation on the surface of malignant
B lymphocytes, which were linked to an impaired
rituximab-mediated CDC and ADCC against lymphoma
cells, and our and others’ clinical data be explained?
Though in vitro and in vivo correlations are often
ambiguous, plasma levels achieved by common doses of
statins used in the clinical routine are much lower than the
concentrations used in the preclinical study. Maximum
plasma concentrations of lovastatin, when given at thera-
peutic single daily doses of 20–80 mg, are reported to be in
the range of 1.53–23.1 ng/ml [17-19]. In contrast, to
achieve a significant abrogation of the anti-lymphoma
effect of rituximab in vitro, lymphoma cells had to be
incubated with lovastatin at concentrations of more than
2,000 ng/ml in vitro. Even the lowest lovastatin concentra-
tion tested (400 ng/ml) was not effective for a significant
impairment of rituximab activity and is still substantially
higher than the documented in vivo peak plasma levels [4].
The same applies to the other statins used such as
atorvastatin. Plasma levels for atorvastatin ranging from
1.8 to 23 ng/ml have been reported in healthy or
hypercholesterolemic individuals [20-23], but the concen-
tration needed to show an adverse influence of statins on
CDC was 275 to 2,750 times higher [4]. However, the
authors observed a reduced binding of the anti-CD20 mAb
ofatumumab to its target epitope in a small patient cohort
treated with atorvastatin 80 mg daily. Taking the available
clinical data and the aforementioned methodological details
of the in vitro study into account, we hypothesize that a
reduction of rituximab binding to CD20 does not necessarily
translate into a reduced anti-lymphoma activity. On the
other hand, additional anti-lymphoma effects of statins
may also be, in part, responsible for the trend toward
improved outcome of patients with statin treatment [24-
26].
The main limitation of our study is the small patient
number, especially for patients treated with statins. A post
hoc power analysis indicated that the power for the log-rank
test for event-free survival was approximately 35%.
Fig. 2 Kaplan–Meier analysis of the overall survival (OS) of patients
without statin use compared with the patients receiving statin
medication during R-CHOP treatment. OS at 5 years was 81.4% in
patients without statins compared with 93.3% in patients who received
them during treatment (HR, 0.58; 95% CI, 0.07–4.55, p=0.6). Median
OS was not reached in both groups. Dashed line patients with statins;
solid line patients without statins
Response after chemotherapy Statin use (n=21) No statin use (n=124) p value
CR/uCR—no. (%) 18 (86) 93 (75)
PR—no. (%) 3 (14) 19 (15)
SD/PD—no. (%) 0 (0) 12 (10) 0.45
Metabolic activity in post-treatment PET Statin use (n=12) No statin use (n=57) p value
No—no. (%) 11 (92) 48 (84)
Yes—no. (%) 1 (8) 9 (16) 0.068
Table 2 Remission rates and
PET response
CR complete remission, uCR
unconfirmed complete remis-
sion, PR partial remission, SD
stable disease, PD progressive
disease
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Furthermore, we did not analyze the cholesterol serum
levels of our patients, but the recently published Japanese
study showed no differences in the clinical outcome of
patients with low levels of serum cholesterol [7].
In summary, we observed that patients taking statins did
not do worse than patients not taking statins. Based on
these data, we currently do not recommend our patients to
stop statin medication during R-CHOP therapy. To further
evaluate the prognostic value of statins in lymphoma
patients and their mechanisms of action, more translational
research is warranted.
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